The organic cation transporter 2 (OCT2, SLC22A2) plays an important role for renal drug elimination. Recent clinical studies indicate an impact of the frequent nonsynonymous c.808G>T (p.270Ala>Ser) polymorphism on renal clearance of metformin and the extent of the metformin-cimetidine interaction. The role of this polymorphism for renal disposition of endogenous compounds and drugs other than metformin has not been investigated. In addition, it is unclear whether the observed genotype dependence of an OCT2-mediated drug-drug interaction might occur also with other OCT inhibitors. To address these issues, we generated human embryonic kidney cells stably expressing wild-type OCT2 or the p.270Ala>Ser variant. No differences in protein expression levels and membrane incorporation pattern were observed between the two cell lines. The p.270Ala>Ser variant significantly impaired uptake kinetics of 1-methyl-4-phenylpyridinium, dopamine, norepinephrine, and propranolol. V max values were significantly reduced for uptake of all four compounds mediated by the p.270Ala>Ser variant compared with wild-type OCT2. In addition, a significant difference in the affinity to wild-type and mutant OCT2 was observed for dopamine (K m dopamine: 932 ؎ 77 versus 1285 ؎ 132 M). Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC 50 wild type versus p.270Ala>Ser 189 versus 895 M, P < 0.001). Our results indicate that the common OCT2 c.808G>T single nucleotide polymorphism significantly alters uptake of endogenous compounds and drugs. Moreover, for selected compounds the extent of OCT2-mediated drug interactions could depend on OCT2 c.808G>T genotype.
Renal secretion is an important pathway for the elimination of many clinically used drugs. Transporters in the renal tubule epithelium mediate drug secretion into urine and thus play a critical role in detoxification. Approximately 40% of all drugs on the market are organic cations (Kim and Shim, 2006) . Various clinically important cationic therapeutics (e.g., metformin), endogenous compounds (e.g., dopamine), and toxic substances [e.g., 1-methyl-4-phenylpyridinium (MPP ϩ )] enter the tubule epithelial cell via organic cation transporters (OCTs) (Wright, 2005; Schömig et al., 2006; Koepsell et al., 2007) . OCTs belong to the solute carrier SLC22A gene family. Three human OCTs have been cloned: OCT1 (SLC22A1), OCT2 (SLC22A2), and OCT3 (SLC22A3). In humans, OCT2, in particular, is important for the renal elimination of organic cations (Motohashi et al., 2002; Shikata et al., 2007; Song et al., 2008a; Wang et al., 2008) . In vitro and in vivo data indicate that inhibition of OCT function by concomitantly administered drugs is a newly recognized mechanism of drugdrug interactions (Somogyi et al., 1987; Bachmakov et al., 2008) .
Several variants in the SLC22A2 gene have been identified (Leabman et al., 2002; Fukushima-Uesaka et al., 2004; Ogasawara et al., 2008; Takane et al., 2008; Wang et al., 2008) . Among all OCT2 protein sequence variants identified so far, the p.270AlaϾSer (c.808GϾT) OCT2 variant is the most common one. The allele frequencies of the c.808GϾT SNP in different populations are 7 to 16% (Leabman et al., 2002) . Some (Kang et al., 2007; Song et al., 2008a,b) , but not all, in vitro studies (Leabman et al., 2002) indicate altered uptake activity of the p.270AlaϾSer OCT2 variant compared with wild-type OCT2. Recent studies in healthy volunteers reported a significantly reduced renal clearance of metformin in subjects with the 808TT genotype compared with the GT and GG groups (Song et al., 2008a; Wang et al., 2008) . Moreover, the extent of inhibition of metformin tubular secretion by cimetidine was significantly lower in healthy volunteers with the 808TT compared with the GT and GG groups (Wang et al., 2008) .
The present in vitro study was designed to extend the previous in vitro and in vivo findings by addressing the following two issues: 1) investigation of OCT2-mediated transport of additional endogenous compounds (dopamine and norepinephrine) and drugs (metformin and propranolol) by p.270AlaϾSer OCT2 variant compared with wild-type OCT2; and 2) characterization of the impact of the p.270AlaϾSer OCT2 variant on the inhibition of uptake by a set of 27 drugs. and tamoxifen were from BioTrend (Cologne, Germany). All other drugs were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Cell Culture and Transfection. HEK293 cells were stably transfected with human SLC22A2 cDNA cloned from human kidney using the mammalian expression vector pcDNA3.1/Hygro(Ϫ) (Invitrogen, Carlsbad, CA). The c.808GϾT mutation was introduced into the vector pcDNA3.1/Hygro(Ϫ)-OCT2 using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Amsterdam, The Netherlands) according to the manufacturer's protocol. Fulllength sequencing confirmed identity with the reference sequence and presence of the c.808GϾT mutation after mutagenesis. Transfectants expressing recombinant wild-type or p.270AlaϾSer OCT2 were selected with hygromycin, and the transfectants were screened for OCT2 expression by real-time reverse transcription-polymerase chain reaction (forward primer 5Ј-CAA TGG CCT ATG AGA TAG TCT-3Ј and reverse primer 5Ј-GCA GCA ACG GTC TCT CTT CTT-3Ј) and immunoblot analyses (see below). The clones with the highest wild-type and p.270AlaϾSer OCT2 expression, respectively, were chosen for further studies. Cells transfected with the pcDNA3.1/Hygro(Ϫ) vector only were used as controls.
Transport Assay in HEK-OCT2 Cells. Transport assays were performed as described previously (Solbach et al., 2008; Zolk et al., 2009 (Zolk et al., 2009) . These potential inhibitors were selected based on previous publications suggesting them as substrates/inhibitors of OCT2 and/or on the presence of physicochemical characteristics generally associated with OCT2 substrates/ inhibitors, such as net positive charge at the amine nitrogen at physiological pH and molecular weight Ͻ500. It is noteworthy that these compounds were selected to cover a broad range of structural diversity.
The cells were incubated with the test solution at 37°C. Uptake was stopped after 2 min by washing the cells three times with ice-cold uptake buffer. Cells were then lysed with 5 mM Tris buffer (pH 7.4) containing 0.1% Triton X-100. The intracellular accumulation of radioactivity was determined by liquid scintillation counting (PerkinElmer, Rodgau-Jügesheim, Germany) and protein concentrations of the lysates were measured with a bicinchonic acid assay (BCA Protein Assay Kit; Peribo Science, Bonn, Germany). The OCT2-mediated net uptake was obtained by subtracting the uptake in vectortransfected cells from that in OCT2 (reference or mutant)-expressing cells.
Michaelis-Menten type nonlinear curve-fitting was carried out to obtain estimates of the maximal uptake rate (V max ) and the concentration at which half the maximal uptake occurs (K m ) (GraphPad Software Inc., San Diego, CA). The IC 50 was estimated by a sigmoidal inhibition model with GraphPad Prism (GraphPad Software) and was fit to the equation V ϭ V 0 /(1 ϩ (I/IC 50 )n) by nonlinear regression. V is the uptake of MPP ϩ in the presence of the inhibitor, V 0 is the uptake of MPP ϩ in the absence of inhibitor, I is the inhibitor concentration, and n is the slope. Data from nonlinear regression are presented as mean Ϯ S.E.M. values. The uptake experiments were repeated at least six times and inhibition experiments at least three times.
To determine the type of inhibitory interaction of metformin with OCT2-mediated MPP ϩ uptake, the uptake of determined in the presence of increasing concentrations of metformin (39 -5000 M). Data were analyzed by the method of Dixon, in which the reciprocal velocity, 1/V, is plotted against the inhibitor concentration. Western Blot Analysis. Human placenta and HEK293 cells (vector control cells or HEK-OCT2 cells) were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 5 mol/l EDTA, and Complete Protease Inhibitors (Roche Applied Science, Mannheim, Germany). Aliquots of denatured protein were subjected to 10% SDS-polyacrylamide gel electrophoresis, and separated proteins were electrophoretically transferred onto nitrocellulose membranes. Blots were probed with a polyclonal OCT2 antibody, which was generated by immunizing rabbits with the peptides RQCRRYEVDWNQSTFD (amino acids 87-102 of human OCT2) and SLDT-NRSRLPLGPCRD (amino acids 109 -124) coupled to keyhole limpet hemocyanin. As a control for loading, blots were also probed with a glyceraldehyde-3-phosphate dehydrogenase antibody (1:2000; HyTest, Turku, Finland) .
To compare levels of plasma membrane expression of wild-type and p.270AlaϾSer OCT2 protein, cell surface proteins were first labeled with sulfo-NHS-SS-biotin, a membrane-impermeable biotinylation reagent (Cell Surface Protein Isolation Kit; Pierce Chemical, Rockford, IL). The cells were subsequently lysed, and then labeled proteins were isolated with immobilized NeutrAvidin Gel according to the manufacturer's instruction. The bound proteins were released by incubating the resin with SDS-polyacrylamide gel electrophoresis sample buffer containing 50 mM dithiothreitol, and expression of OCT2 was analyzed by Western blotting as described above.
Immunofluorescence. Cellular localization of OCT2 was analyzed by immunofluorescent staining and confocal microscopy with a Zeiss LSM 5 Pascal system using a Zeiss Axiovert microscope (Carl Zeiss, Jena, Germany). Incubation with the OCT2 antibody (1:500) was followed by incubation with an Alexa Fluor 488 conjugated secondary antibody (1:10,000; Invitrogen, Carlsbad, CA). Nuclei were counterstained with Hoechst 33342 stain.
Homology Modeling. Sequence-based structural relatives to human OCT2 were searched with the Protein Homology/analogY Recognition Engine Phyre, version 0.2 (Bennett-Lovsey et al., 2008) . The glycerol-3-phosphate transporter (GlpT) of Escherichia coli (Protein Data Bank code 1PW4) was returned as the highest score hit, followed by the multidrug transporter EmrD from E. coli (code 2GFP), and the lactose permease from E. coli (code 1PV7).
Subsequent homology modeling of human OCT2 was based on the crystal structure of GlpT. The human SLC22A2 gene was compared with the ortholog genes from Mus musculus, Rattus norvegicus, Sus scrofa, Pan troglodytes, Oryctolagus cuniculus, Gallus gallus, and Canis lupus familiaris to identify conserved regions. This multiple alignment was done with ClustalW2. The information was then used to optimize the binary alignment between human SLC22A2 and GlpT sequences with the LALIGN program. Finally, the threedimensional model was constructed with SwissModel and visualized with DeepView, version 3.7.
Statistical analysis. Differences between two groups were tested by the Student's t test for unpaired data. Data are expressed as mean Ϯ S.E.M. values. p Ͻ 0.05 was considered statistically significant.
Results

Expression and Subcellular Localization of the p.270Ala>Ser
Variant. Stable transfection of the HEK293 cell line with SLC22A2 cDNAs encoding either the wild-type human OCT2 or the p.270AlaϾSer mutant OCT2 yielded two clones with substantial OCT2 expression at comparable levels, as verified by real-time reverse transcription-polymerase chain reaction (expression of c.808GϾT SLC22A2 mRNA normalized to ␤-actin, relative to wild-type SLC22A2 expression: 1.0 Ϯ 0.17, N.S.) and Western blotting of whole cell lysates (Fig. 1a) and cell surface protein extracts (Fig. 1b) . Both the wild-type and the mutant OCT2 protein were integrated into the plasma membrane of HEK-OCT2 cells (Fig. 1c) and were functionally active, as revealed by transport assays (Fig. 2) (20.9 M) . In addition, we also tested the impact of the mutant OCT2 protein on dopamine, norepinephrine, metformin, and propranolol uptake. V max values for p.270AlaϾSer were significantly lower for dopamine, norepinephrine, and propranolol than those of the OCT2 reference. In particular, transport of propranolol was markedly impaired with a 56% ( p Ͻ 0.01) reduction in V max . Moreover, substrate-specific changes in the affinities to mutant OCT2 were observed for dopamine with an increase in K m compared with the reference OCT2 (wild-type OCT2 versus mutant OCT2: 932 Ϯ 77 versus 1285 Ϯ 132 M, p Ͻ 0.05).
To clarify the type of interaction of metformin with OCT2-mediated transport of MPP ϩ , Dixon plot analyses were performed (Fig. 3) . The lines drawn for each concentration of substrate intersect at a single point above the x-axis, indicating competitive inhibition. K i values determined from the Dixon plots were 286 and 590 M for wild-type and p.270AlaϾSer OCT2, respectively.
To determine whether the p.270AlaϾSer mutation altered interaction of OCT2 with other molecules, we carried out inhibition studies. We investigated the inhibition of [ 3 H]MPP ϩ (10 M) uptake by a set of 27 structurally unrelated (Tanimoto pairwise similarity index 0.25) cationic drugs. As summarized in Table 2 Based on the observation that the extent of inhibition of metformin tubular secretion by cimetidine was significantly lower in subjects with the 808TT genotype than in those with the GT and GG genotype (Wang et al., 2008) , we also addressed the question whether the p.270AlaϾSer variant was less sensitive to cimetidine inhibition than the wild-type OCT2 transporter. As shown in Fig. 4b , the IC 50 value for inhibition of metformin uptake by mutant OCT2 was significantly higher than that for wild-type OCT2 (45 versus 11 M, p Ͻ 0.01).
Location of the p.270Ala>Ser SNP and Sequence Alignment. The predicted location of the p270AlaϾSer variant in the secondary structure of OCT2 is shown in Fig. 5, a and b . It occurs in transmembrane domain 6 facing the extracellular membrane surface. Figure 5c shows the amino acid sequence of human OCT2 at position 270 with flanking amino acids, which was aligned with the orthologs from chimpanzee, Bornean orangutan, mouse, rat, swine, dog, rabbit, cow, and chicken. The small polar amino acid Thr is conserved among all species except for some species within the family of man-like primates, such as human and chimpanzee, in which the Thr is replaced by the small nonpolar amino acid Ala at position 270.
Discussion
The major findings of the present investigation were that the OCT2 c.808GϾT (p.270AlaϾSer) SNP does not affect expression and membrane localization but rather causes compound-specific alterations of transport function compared with wild-type OCT2. Although the p.270AlaϾSer variant had only minor or no effects on the substrate affinity, V max was decreased for most compounds investigated. How- ever, the degree of reduction varied substantially (10 -56% reduction) between these compounds. Moreover, p.270AlaϾSer OCT2 was less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2, whereas the remaining drugs tested in this study showed nonsignificantly different IC 50 values for inhibition of MPP ϩ uptake in cells expressing p.270AlaϾSer or wild-type OCT2. Altogether, the p.270AlaϾSer SNP markedly decreased maximum transport rate and impaired the inhibitory interaction with MPP ϩ uptake by some but not all drugs. These findings highlight the need for testing several compounds when in vitro functional differences between a reference transporter and its protein sequence variant are characterized.
In the first in vitro study on the functional consequences of SLC22A2/OCT2 polymorphisms, Leabman et al. (2002) reported nonsignificant differences for the affinity of the prototype substrate MPP ϩ to wild-type and p.270AlaϾSer OCT2, which is in line with the present findings. In contrast, using the same substrate, Kang et al. (2007) reported a higher K m value for p.270AlaϾSer OCT2 compared with wild-type OCT2 (K m 3.5 versus 7.0 M), although they did not state whether this difference was statistically significant. In accordance with our results, Kang et al. (2007) observed lower V max values for p.270AlaϾSer OCT2 compared with wild-type OCT2.
Several clinical observations suggest a functional role of the p.270AlaϾSer variant. For example, a lower prevalence of OCT2 p.270AlaϾSer was reported for patients with essential hypertension . Although the molecular mechanism of this clinical observation has not been elucidated so far, our in vitro data with dopamine and norepinephrine indicate that the p.270AlaϾSer variant alters transport of endogenous compounds possibly resulting in alterations of, e.g., blood pressure. Drugs such as metformin are dependent on renal transporters for their ultimate urinary elimination. Interindividual variations in the renal secretion of metformin have been documented (Sirtori et al., 1978; Yin et al., 2006) . Therefore, recent studies in healthy volunteers have investigated the effect of the c.808GϾT genotype on renal elimination of metformin (Song et al., 2008a; Wang et al., 2008) . Renal metformin clearance was significantly reduced, resulting in higher peak plasma concentration (C max ) and area under the curve in individuals with the c.808TT genotype (p.270Ser/Ser) compared with carriers of wild-type alleles. These studies highlight the potential importance of this polymorphism for drug elimination.
In an attempt to directly demonstrate the significance of the SLC22A2 c.808GϾT SNP for transport of metformin, in vitro studies were performed. Using transiently transfected HEK cells, Song et al. (2008a) wild-type OCT2. Likewise, we observed no significant differences for the affinity of metformin to wild-type and p.270AlaϾSer OCT2. However, using stably transfected HEK cells, we also did not find a significant difference in V max . We cannot explain these discrepant findings definitely; however, one reason might relate to the different models of transfection (transient versus stable). It should be noted that in the present study particular attention was drawn to wild-type and variant OCT2 cell surface expression levels.
By focusing on drug-drug interactions, a recent clinical study (Wang et al., 2008) determined the effect of cimetidine coadministration (an OCT inhibitor) on genotype-dependent metformin renal clearance (CL r ). In subjects homozygous for the c.808GϾT mutation only a small change of metformin CL r (12.5%) was observed when cimetidine was coadministered compared with the much larger change in subjects with the GT or the GG genotype (26.0 and 42.4%). That finding clearly suggests that TT carriers (p.270Ser/Ser) are much less sensitive to the inhibition by cimetidine. This is in agreement with our finding that metformin uptake was less sensitive to inhibition by cimetidine in cells expressing the p.270AlaϾSer variant compared with wild-type OCT2. It is noteworthy that our results indicate that some compounds may act as competitive inhibitors of OCT2, as exemplified for inhibition of OCT2-mediated MPP ϩ uptake by metformin.
The homology model of the three-dimensional structure of OCT provides a means to interpret the effect of specific residues on transport activity (Zhang et al., 2005; Pelis et al., 2006; Koepsell et al., 2007) . The template structure of GlpT was used to develop a structural model of human OCT2. Similar to the model constructed by Zhang et al. (2005) , the amino acid Ala-270 was predicted to face the outer pore of the transporter. However, there are distinct differences in the absolute position of the Ala-270 residue. In the present study, the amino acid Ala-270 was predicted to lie within the transmembrane domain 6 directly facing the extracellular membrane surface, whereas in the model developed by Zhang et al. (2005) Ala-270 was located in the short extracellular loop between transmembrane helix 5 and 6. Nevertheless, Ala-270 locates in a region of the OCT2 protein that is potentially important for substrate recognition. This raises the possibility that the p.270AlaϾSer SNP may impair substrate-transporter interactions. It is interesting to note that Ala-270 occurs only in some species from the Hominidae family, whereas in orthologs from other species Thr, a small polar amino acid like Ser, is conserved at this position. It is tempting to speculate that Thr in OCT2 orthologs affects OCT2 transport function similarly to the p.270AlaϾSer variant and contributes in part to the observed species differences, for example, between human and rabbit OCT2 (Suhre et al., 2005) .
In summary, we demonstrated that the common SLC22A2 c.808GϾT SNP (p.270AlaϾSer) significantly alters uptake of endogenous compounds and drugs. Genotype-dependent alterations in the affinity (K m ) seem to be substrate-dependent, whereas for most compounds investigated we found significantly reduced maximal transport rates (V max ). Moreover, for selected compounds the extent of OCT2-mediated drug interactions could depend on the SLC22A2 c.808GϾT genotype.
